Page last updated: 2024-09-03

n(6)-carboxymethyllysine and Active Hyperemia

n(6)-carboxymethyllysine has been researched along with Active Hyperemia in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (50.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Baer, DJ; Ferrucci, L; Gebauer, SK; Novotny, JA; Semba, RD; Silber, HA; Sun, K; Talegawkar, S; Turner, R	1
Cai, W; He, JC; Li, Z; Linden, E; Uribarri, J; Vlassara, H; Winston, J; Xue, C	1

Trials

1 trial(s) available for n(6)-carboxymethyllysine and Active Hyperemia

Article	Year
Dietary intake of advanced glycation end products did not affect endothelial function and inflammation in healthy adults in a randomized controlled trial. The Journal of nutrition, 2014, Volume: 144, Issue:7 Topics: Aged; Biomarkers; Dietary Proteins; Endothelium, Vascular; Female; Follow-Up Studies; Glycation End Products, Advanced; Humans; Hyperemia; Inflammation Mediators; Lysine; Maillard Reaction; Male; Maryland; Middle Aged; Peripheral Vascular Diseases; Receptor for Advanced Glycation End Products; Receptors, Immunologic; Risk; Severity of Illness Index; Solubility; Vascular Resistance; Vasculitis	2014

Article

Year

Dietary intake of advanced glycation end products did not affect endothelial function and inflammation in healthy adults in a randomized controlled trial.

The Journal of nutrition, 2014, Volume: 144, Issue:7

Topics: Aged; Biomarkers; Dietary Proteins; Endothelium, Vascular; Female; Follow-Up Studies; Glycation End Products, Advanced; Humans; Hyperemia; Inflammation Mediators; Lysine; Maillard Reaction; Male; Maryland; Middle Aged; Peripheral Vascular Diseases; Receptor for Advanced Glycation End Products; Receptors, Immunologic; Risk; Severity of Illness Index; Solubility; Vascular Resistance; Vasculitis

2014

Other Studies

1 other study(ies) available for n(6)-carboxymethyllysine and Active Hyperemia

Article	Year
Endothelial dysfunction in patients with chronic kidney disease results from advanced glycation end products (AGE)-mediated inhibition of endothelial nitric oxide synthase through RAGE activation. Clinical journal of the American Society of Nephrology : CJASN, 2008, Volume: 3, Issue:3 Topics: Adult; Aged; Case-Control Studies; Cells, Cultured; Cross-Sectional Studies; Endothelial Cells; Endothelium, Vascular; Female; Glomerular Filtration Rate; Glycation End Products, Advanced; Humans; Hyperemia; Lysine; Male; Middle Aged; Nitric Oxide Synthase Type III; Pyruvaldehyde; Receptor for Advanced Glycation End Products; Receptors, Immunologic; Regional Blood Flow; Renal Insufficiency, Chronic; RNA Interference; RNA, Messenger; RNA, Small Interfering; Severity of Illness Index; Skin; Up-Regulation	2008

Article

Year

Endothelial dysfunction in patients with chronic kidney disease results from advanced glycation end products (AGE)-mediated inhibition of endothelial nitric oxide synthase through RAGE activation.

Clinical journal of the American Society of Nephrology : CJASN, 2008, Volume: 3, Issue:3

Topics: Adult; Aged; Case-Control Studies; Cells, Cultured; Cross-Sectional Studies; Endothelial Cells; Endothelium, Vascular; Female; Glomerular Filtration Rate; Glycation End Products, Advanced; Humans; Hyperemia; Lysine; Male; Middle Aged; Nitric Oxide Synthase Type III; Pyruvaldehyde; Receptor for Advanced Glycation End Products; Receptors, Immunologic; Regional Blood Flow; Renal Insufficiency, Chronic; RNA Interference; RNA, Messenger; RNA, Small Interfering; Severity of Illness Index; Skin; Up-Regulation

2008